CAJ | 학술논문

目的：探讨仙灵骨葆胶囊联合阿仑膦酸钠片、鲑降钙素对骨质疏松症患者的治疗作用。方法：选取2013年5月-2014年5月期间我院门诊和住院部就诊的骨质疏松症患者79例，采用随机数字表法将患者分为对照组（n=39，阿仑膦酸钠片联合鲑降钙素药物治疗）和观察组（n=40，在对照组基础上采用仙灵骨葆胶囊治疗），比较两组临床疗效。结果：观察组显效率和治疗有效率均明显高于对照组（P ＜0.05）。治疗前，两组患者骨密度值（BMD）、血磷（S-P）、血钙（S-Ca）、血清碱性磷酸酶（ALP）和血骨钙素（BGP）水平比较差异无统计学意义（P ＞0.05）。治疗3~12个月后，观察组 BMD 值明显高于同组治疗前，且明显高于对照组。治疗后，全部患者 S-P、S-Ca 和 BGP 水平均明显高于治疗前，血清 ALP 明显低于治疗前，其中观察组 S-P、S -Ca 和 BGP 水平均明显高于对照组，ALP 水平明显低于对照组，比较均有统计学意义。两组药物不良反应发生率比较差异无统计学意义（P ＞0.05）。结论：仙灵骨葆胶囊联合阿仑膦酸钠片、鲑降钙素对骨质疏松症患者具有明显的治疗作用，有助于改善骨代谢指标。
목적：탐토선령골보효낭연합아륜련산납편、해강개소대골질소송증환자적치료작용。방법：선취2013년5월-2014년5월기간아원문진화주원부취진적골질소송증환자79례，채용수궤수자표법장환자분위대조조（n=39，아륜련산납편연합해강개소약물치료）화관찰조（n=40，재대조조기출상채용선령골보효낭치료），비교량조림상료효。결과：관찰조현효솔화치료유효솔균명현고우대조조（P ＜0.05）。치료전，량조환자골밀도치（BMD）、혈린（S-P）、혈개（S-Ca）、혈청감성린산매（ALP）화혈골개소（BGP）수평비교차이무통계학의의（P ＞0.05）。치료3~12개월후，관찰조 BMD 치명현고우동조치료전，차명현고우대조조。치료후，전부환자 S-P、S-Ca 화 BGP 수평균명현고우치료전，혈청 ALP 명현저우치료전，기중관찰조 S-P、S -Ca 화 BGP 수평균명현고우대조조，ALP 수평명현저우대조조，비교균유통계학의의。량조약물불량반응발생솔비교차이무통계학의의（P ＞0.05）。결론：선령골보효낭연합아륜련산납편、해강개소대골질소송증환자구유명현적치료작용，유조우개선골대사지표。
Objective: To discuss the efficacy of Xianlinggubao capsule combined with alendronate sodium tablets and salmon calcitonin in the treatment of the patients with osteoporosis. Methods: Seventy-nine outpatients and inpatients with osteoporosis in our hospital from May, 2013 to May, 2014 were selected and divided into a control group (n=39, received alendronate sodium tablets and salmon calcitonin treatment) and an observation group (n=40, received Xianlinggubao capsule on the basis of the control group) by digital randomized method. The clinical efficacy was compared between two groups. Results:The efficiency and treatment effectiveness of the observation group were significantly higher than those of the control group (P<0.05). There was no statistical significance in bone mineral density (BMD), blood phosphorus (S-P), blood calcium (S-Ca), serum alkaline phosphatase (ALP) and osteocalcin (BGP) between two groups before treatment (P>0.05). The BMD of the observation group was significantly higher 3 ~ 12 months after treatment than before, and that of the control group. The S-P, S-Ca and BGP levels of all patients were significantly higher while the serum ALP was significantly lower after treatment than before (P<0.05). There were no obvious differences in adverse drug reaction between two groups (P>0.05). Conclusion: Xianlinggubao capsule combined with alendronate sodium tablets and salmon calcitonin shows an obvious therapeutic effect in the treatment of the patients with osteoporosis and can improve bone metabolism index.